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EXPERIMENTAL AND CLINICAL STUDIES
The following workshops reported on the advancements on
1,3-β-glucan biology in terms of understanding the molec-
ular basis for the cellular reactions induced as well as new
methods for analysis and the clinical applications, particu-
larly concerning fungal infections.
Theﬁrstglucanworkshopwasorganizedin1990withthe
purposetodrawattentiontotheimportanceof1,3-β-glucan,
one of the major constituents of fungal cell walls, as a bioac-
tive agent in our environment [1]. The workshop reviewed
available data and through fruitful discussions encouraged
further research in the area. This was followed by a succes-
sion of similar workshops in 1993, 1994, and 1997 [2–4].
Although the number of researchers in this ﬁeld has re-
mained fairly limited over the years, progress since the ﬁrst
workshophasbeensigniﬁcant.Severalsubjectsatthepresent
workshop are similar to those treated 17 years ago but there
has been an imposing increase in depth and breath of the
knowledge.
In the ﬁrst workshop, a main interest was the method-
ology of the measurement of 1,3-β-glucan and the levels
present in the environmental and in clinical specimens. In-
formation was also presented on the inﬂuence of 1,3-β-
glucan on inﬂammatory and immunological systems. It was
suggested that 1,3-β-glucan could be an important environ-
mental and clinical agent related to human diseases but there
was a lack of both experimental and clinical studies. Against
this short background of previous workshops it is time again
to present the advances in the diﬀerent ﬁelds, now with an
emphasis on molecular biology for the understanding of the
eﬀects and experience from investigations on humans for
clinical and environmental risk evaluations.
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INVENTORY OF 1,3-β-GLUCAN LEVELS IN
THE ENVIRONMENT
RagnarRylander
BioFact Environmental Health Research Center, Bjorkasv 21,
44391Lerum,Sweden2 Mediators of Inﬂammation
INTRODUCTION
The mould cell wall agent 1,3-β-glucan has a number of bio-
logical eﬀects after inhalation and injection [1]. The purpose
of this presentation is to review data from some major stud-
ies on the levels of 1,3-β-glucan in occupational and general
environments.
METHODOLOGICAL ISSUES
The amount of 1,3-β-glucan in environmental samples can
be determined using two diﬀerent analytical methods. One
methodistheLimulusassayusingaglucanspeciﬁclysate[2].
A sample of airborne or sedimented dust is extracted in wa-
ter with NaOH added or during heating to 130◦C. This pro-
cedure is required to dissolve the triple helix of the glucan
molecule and render it accessible to the reagent in the test.
If this treatment is not performed, the analysis will comprise
only the water soluble portion of the environmental glucan
which is 10% or less than the total [3]. The method is similar
to the standard method to analyse bacterial endotoxin where
a speciﬁc lysate is also used. The method has a high sensitiv-
ity (around 1pg/mL) but is not speciﬁc for moulds as pollen
and certain vegetable ﬁbres also contain 1,3-β-glucan.
Another method to determine that 1,3-β-glucan is based
on a speciﬁc enzyme immunoassay [4]. It uses puriﬁed poly-
clonal rabbit anti-1,3-β-glucan antibodies and laminarin (a
1,3-β-glucan) asthe coatedantigen and calibration standard.
The detection threshold for this method is 0.26μg/m3.N o
datacomparingtheresultsfromthetwomethodsinthesame
sample have been published.
ENVIRONMENTAL MEASUREMENTS
TheLimulusmethod
The ﬁrst study where the level of 1,3-β-glucan was measured
inindoorenvironmentscomprisedanumberofﬂats,daycare
centers, and a post-oﬃce [5]. After that a number of stud-
ies in indoor environments and occupational exposures have
been published. The results are summarised in Table 1.
The highest values were recorded in animal conﬁnement
buildings. The high levels in cotton cardrooms with a rela-
tively small variation suggest a reaction with the cotton ﬁbre.
Theimmunologicalmethod
Anumberofﬁeldstudiesreportlevelsofindoor1,3-β-glucan
using the immunological method. They are summarised in
Table 2.
Comments
A review of most of the available data on 1,3-β- gl u c a ni nd i f -
ferent environments demonstrates a variation of dose levels
within the diﬀerent environments. Values using the Limulus
method are usually considerably lower illustrating the very
high sensitivity of that method.
In several of the studies reviewed above, the levels of 1,3-
β-glucan have been related to the presence of symptoms or
Table 1: 1,3-β-glucan (Limulus lysate analysis) in diﬀerent envi-
ronments.
Environment n Range References
Airborneng/m3
Poultry farms 39 4.1–870 [3]
Waste collection 14 2.0–34.0 [6]
Waste collection 25 5–220 [7]
Cotton cardroom 15 1037–7286 [8]
Mouldy homes 26 0–7.6 [9]
Recycling 136 0–137 [11]
Wood processing 24 4.5–330 [8]
Horse stables 20 0–76.5 [8]
Swine stables 9 78.6–425 [8]
Homes, indoor/outdoor 19 0.3–9.4 [9]
Airborneagitated ng/m3
Mouldy homes 26 0–9.3 [10]
School 15 0–27.4 [12]
Row houses 75 0–19.0 [13]
Day care 9 1.4–11.0 [14]
House 6 5–106 [15]
Sedimented dustng/mg
Mouldy homes 26 1.5–173 [9]
Cotton cardroom 4 572–850 [8]
Table 2: 1,3-β-glucan (immunological method analysis) in diﬀer-
ent environments.
Environment n Range References
Airborne μg/m3
Waste collectors 118 0–30.8 [16]
Saw mills 37 0.4–92.5 [17]
Sedimented dust
Homes (μg/g) 476 98–10000 [18]
Homes (μg/m2) 75 157–3652 [19]
Homes (μg/m2, GM) 211 0–243 [20]
Homes (μg/g, percentiles) 395 469–4065 [21]
clinical measures of inﬂammation, either comparing high
and low/control exposures or on a dose-response basis. A re-
lation has been found for the extent of respiratory symptoms
[11], pulmonary function [19], and blood lymphocyte num-
bers[6].Althoughsigniﬁcantrelationshavebeenfound,they
do not prove causality for 1,3-β-glucan as the environments
studied contain a variety of biologically active agents such as
bacterial endotoxin, fungal toxins, fungal enzymes, and mi-
c r o b i a lc e l lw a l la g e n t sf r o mav a r i e t yo fd i ﬀerent microbes.
Further studies are required to assess the role of 1,3-β-glucan
for these eﬀects. For preventive purposes, it could be possi-
ble to use the level of 1,3-β-glucan as a descriptor of the ex-
posure and as a basis for “action values”. The available data
are not yet suﬃcient to suggest those action values although
25ng/mg ﬂoor dust has been suggested for an increased riskEuropean Brain and Behaviour Society 3
f o rh i g hl e v e l so fI g E[ 10] .F u r t h e rw o r ki sr e q u i r e dt od e ﬁ n e
such values.
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PULMONARY EXPOSURE TO CANDIDA
SOLUBLE CELL WALL 1,3-β-GLUCAN INDUCES LUNG
INFLAMMATION IN MICE
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N.Ohno,4 Y.Adachi,4 K.Ishibashi,4 andT.Yoshikawa2
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It is widelyrecognized that cell wall components of mi-
croorganisms may induce variety of host reactions.The cell
wall component lipopolysaccharide of Gram-negative bacte-
ria and peptidoglycan of Gram-positive bacteria can activate
macrophages to release proinﬂammatory molecules, result-
ing in circulatory shock and multiple organ failure [1, 2].
On the other hand, the bioactivity of cell wall component(s)
of fungi has not been fully elucidated, especially in vivo. In
a previous study, we isolated soluble 1,3-β-glucan (CSBG)
from Candida albicans [3]. In the current work, we investi-
gated the eﬀects of CSBG on the respiratory systems in mice
after an intratracheal injection of 50μg. The animals were
sacriﬁced at 24 hours after this exposure, then, a broncho-
alveolar lavage was performed, and the cells were stained
with Diﬀ-Quick. The results on cells are found in Figure 1.
There was an inﬁltration of neutrophils, eosinophils, and
mononuclearcells,whichwasconcomitantwithanincreased
local expression of proinﬂammatory cytokines such as tu-
mor necrosis factor-α, interleukin (IL)-1β, IL-6, as well as4 Mediators of Inﬂammation
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Figure 1: Cells in lavage ﬂuid after intratracheal instillation of sus-
pension ﬂuid (vehicle), 1,3-β-glucan (CSBG), and degraded CSBG
(DEG-CSBG). n = 8–12 in each group. Data are mean ± SEM.
∗P>. 05 versus other treatment.
chemokines such as macrophage inﬂammatory protein-1α,
macrophage chemoattractant protein-1, normal T cells and
their secretion, and eotaxin. The lung inﬂammation with
enhanced expression of proinﬂammatory proteins caused
by CSBG was directly related to its structure, since struc-
turally degraded products of CSBG by formic acid induced
negligible responses in the lung. Taken together, these data
suggest that pulmonary exposure to CSBG in the form
and the dose applied here can induce lung inﬂammation
throughenhancedexpressionsofproinﬂammatorycytokines
and chemokines. In contrast to these results, other studies
have not found an inﬂammatory response neither in ani-
mals [4] nor in humans [5]. This discrepancy is probably
due to diﬀerences in dose and solubility of the 1,3-β-glucans
used and/or the exposure modes (intratracheal administra-
tion versus inhalation exposure). It illustrates the complexity
in the eﬀects of diﬀerent glucans and further studies need to
be undertaken to relate the diﬀerent cellular reactions to risk
for diseases.
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INNATE IMMUNE RESPONSE TO FUNGAL β-GLUCANS
VIA THE SPECIFIC CELL SURFACE RECEPTOR DECTIN-1
YoshiyukiAdachi
LaboratoryforImmunopharmacologyandMicrobial
Products,TokyoUniversityofPharmacyandLifeSciences,
1432-1Horinouchi,Hachioji,Tokyo192-0392,Japan
INTRODUCTION
Dectin-1 is a speciﬁc receptor for 1,3-β-glucans which is ex-
pressed on various kinds of leukocytes, such as macrophages,
neutrophils,anddendriticcells.Itplaysanimportantrolefor
activating innate immune response to fungal infection and
functions as a signaling receptor for the activation of super-
oxide production and inﬂammatory gene expression by the
NF-κB-activation pathway.
There is a need to further characterize the stimulatory
1,3-β-glucan agonists for Dectin-1 in view of the diversity of
thevariousphysicochemicalpropertiesof1,3-β-glucanssuch
as branching ratio, length of branched glucosyl residues, de-
gree of polymerization of main glucosyl chain and solubility.
In terms of branching structure 1,3-β-glucans may be classi-
ﬁed into three major groups: (1) a monoglucosyl branched
linear 1,3-β-glucan as represented by Soniﬁlan (SPG), a
soluble glucan obtained from liquid-cultured extracellu-
lar polysaccharide of Schizophyllum commune. (2) Tree-like
branched main 1,3-glucosyl linkage with 1,6-monoglucosyl
branched1,3-β-glucansasrepresentedbyLentinanandSCG,
which are extracted from the fruit body of edible mush-
rooms. (3) a linear 1,3-β-glucan with various lengths of the
1,6-glucosyl chain as represented by CSBG and OX-CA from
yeast (Candida albicans)o rZ y m o s a n( Saccharomyces cere-
visiae).
In this study, we used several structurally deﬁned and
physicochemical diﬀerent 1,3-β-glucans and evaluated in-
nate immune responses such as NF-κB activation and cy-
tokine production from Dectin-1-expressing cells.
RESULTS AND DISCUSSION
Molecular mechanisms for 1,3-β-glucan recognition and NF-
κBactivationinDectin-1transfectant
Zymosan has been used as a model compound of yeast mi-
croorganisms and stimulates macrophages mainly through
TLR2- and Dectin-1-mediated recognition. In order to
examine the contribution of Dectin-1 in TLR2/MyD88-
mediated NF-κB activation, various Dectin-1 mutants were
tested in TLR2 coexpressed HE293 transfectant. The NF-κB
activation in TLR2 transfectant was signiﬁcantly enhanced
by coexpression of wild-type Dectin-1. The Dectin-1 mu-
tants, in which amino acid residues of extracellular Trp221European Brain and Behaviour Society 5
and His223 (carbohydrate recognition domain) or intra-
cellular Tyr15 (ITAM motif) are replaced with alanine or
phenylalanine, had a lower activation of NF-κB. This is
comparabletoTLR2-alone-expressedHEK293[1].However,
wild-type Dectin-1 transfectant without TLR2 did not re-
spond to stimulation with Zymosan. In the case of stimu-
lation of Dectin-1/TLR2 coexpressed HEK293 transfectant
with puriﬁed particulate 1,3-β-glucan (OX-CA), the cell
showed no activation of NF-κB.
These results indicate that Dectin-1 functions as a cos-
timulatory signaling receptor for TLR2-mediated NF-κBa c -
tivationinHEK293,andZymosanmayhavemultipleagonist
eﬀects, not only as a β-glucan, but also involving TLR2 reac-
tive ligands.
Structure-activity relationship on Dectin-1/Card9-mediated
NF-κBactivation
Card9 is newly identiﬁed signaling molecule in innate im-
mune response and mediates Dectin-1-related NF-κBa ct i v a -
tion. To examine which type of 1,3-β-glucan can stimulate
the Dectin-1/Card9/Bcl10 signaling pathway, various 1,3-β-
glucans were tested, using Dectin-1/Card9/Bcl10 expressing
HEK293Ttransfectant.IncubationofthecellswithZymosan
a n dO X - C As h o w e de n h a n c e dN F - κB activation, but CSBG
(the soluble form of OX-CA), SCG, and SPG did not in-
crease the NF-κB-assisted luciferase expression [2]. These re-
sults suggest that the particulate form of 1,3-β-glucan stimu-
latesDectin-1/Card9/Bcl10signaling,andthatthisactivation
pathway does not require TLR2-reactive ligands.
Innateimmuneresponsetosoluble1,3-β-glucansin
Dectin-1knockoutmice
Although the above results suggest that only particulate
1,3-β-glucans are active on the Dectin-1-mediated immune
response, it has been demonstrated that a soluble 1,3-β-
glucan is immune stimulatory to leukocytes [3]. To in-
vestigate the Dectin-1-mediated signaling of soluble 1,3-β-
glucan, bone marrow-derived dendritic cells (BMDC) from
dectin-1−/− mice were used in a cytokine production as-
say [4]. TNF-α production from dectin-1+/+-derived BMDC
was increased by coincubation with OX-CA or SCG, but the
cells from dectin-1−/− mice did not show any signiﬁcant
production in response to the 1,3-β-glucans. On the con-
trary, the lipopolysaccharide-induced TNF-α production by
dectin-1−/− BMDC was similar to that of dectin-1+/+. These
results suggest that the immune response to soluble 1,3-β-
glucanalsorequirestheDectin-1moleculeforcellactivation.
CONCLUSION
Dectin-1 plays an important role for leukocyte activation
in response to particulate 1,3-β-glucans and also to solu-
ble forms with tree-like branched 1,3- and 1,6-β-glucosyl
linkage. The Dectin-1-mediated activation signaling induced
by such soluble 1,3-β-glucans may require other signaling
molecules which are defect in HEK293 and which are able
to support the known signaling molecules including Syk,
Card9, and Bcl10.
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EFFECTS OF INHALED 1,3-β-GLUCAN:
PROPOSAL FOR A MODEL
RagnarRylander
BioFact Environmental Health Research Center, Bjorkasv 21,
44391Lerum,Sweden
INTRODUCTION
It has been shown above that 1,3-β-glucans are present in
many general and occupational environments and that they
induce cell activation through receptors such as Dectin-1. A
risk assessment of exposure to 1,3-β-glucans in the environ-
ment is complicated by the simultaneous presence of a vari-
ety of other agents including microbial cell wall agents such
asbacterialendotoxin.Anunderstandingofthebiologicalef-
fects of 1,3-β-glucan must thus be based mainly on informa-
tion derived from experiments with the pure substance. In
the following an attempt is made to synthesize the available
information on the toxicity of 1,3-β-glucan with the goal to
p r o p o s eam o d e lf o rt h er e a c t i o n sa f t e ri n h a l a t i o na te x p o -
sure levels similar to those encountered in occupational and
general environments.
EXPERIMENTAL EVIDENCE
The eﬀects of puriﬁed 1,3-β- g l u c a nh a v eb e e ns t u d i e di na
number of studies on animals and humans as previously re-
ported [1]. A possible general error in such studies is that the6 Mediators of Inﬂammation
extraction of 1,3-β-glucan from the fungal cell wall might af-
fect its chemical characteristics and hence the biological ef-
fect. It is also important to recognize that any eﬀect stud-
ied is dependent on the dose and that the dose-response
is not always linear but might have a U-form (Hormesis
dose-response). The absence of an eﬀect at a low dose thus
does not contradict the possibility that it may occur at a
higher dose. This might explain some of the conﬂicting data
in the literature regarding the stimulation of inﬂammatory
cytokines by 1,3-β-glucan. In inhalation experiments with
doses similar to those found in the environment, there is no
evidence for an inﬂammatory response [2]. At high dose lev-
els, however, and using water soluble forms of 1,3-β-glucan,
an inﬂammation can be induced and cytokine stimulation
has been reported in in vitro experiments (see reviews in
[1, 3]).
It has been demonstrated that 1,3-β-glucan inﬂuences
the immune system. The leukocyte invasion into the airways
induced by an acute inhalation of endotoxin is blunted by
a previous inhalation of 1,3-β-glucan [4]. The secretion of
TNFα from peripheral blood monocytes was decreased after
an acute inhalation of 1,3-β-glucan [5, 6]. A depression of
the inﬂammatory response could also explain the prolonged
survival seen in mice with polymicrobial sepsis, presumably
by preventing the increase in transcription factor NF-κB[ 7].
This blunting of the inﬂammatory response could be in-
terpreted as beneﬁcial but conceptually it represents an in-
terference with normal defence mechanisms against inhaled
agents particularly microbes. In chronic exposures the nor-
mal adaptation to endotoxin does not take place if 1,3-β-
glucan is given simultaneously; another example of interfer-
ence with defence mechanisms [8].
Other data suggest that 1,3-β-glucan supports the Th2-
related maturation of lymphocytes, increases the number of
eosinophils in the airways after long-term inhalation expo-
sure [9], and potentiates an ovalbumin induced eosinophilia
[6]. A study in mice demonstrated that 1,3-β-glucan treat-
mentsupportedaTh2-dependentantibodyresponsetooval-
bumin, suggesting that 1,3-β-glucan alters the susceptibility
to environmental antigens [10].
T h e r ei se v i d e n c ef o rt h i se ﬀect of 1,3-β-glucan in pop-
ulation studies. An increased proportion of persons with
atopic sensitization or total IgE has been reported from
mouldy environments [11]. A relationship has been found
between airborne viable spores and total IgE levels in chil-
dren [12]. A relation between markers of atopy and expo-
sure to moulds was found in several studies [13–15]. An in-
creased incidence of atopic persons was found among per-
sons living in houses with higher levels of 1,3-β-glucan [16].
One study reported an association between 1,3-β-glucan in
ﬂoor dust and the amount of IgE and the proportion of
blood eosinophils but not with cellular markers of inﬂam-
mation [17]. Among children at risk for allergy, exposure to
Aspergillus at home was related to a lower content of Th1 cy-
tokines, such as Interferon γ (IFNγ), TNFα, and Interleukin-
2 secreted from T-cells [18]. A previously described develop-
ment of allergy in adults working in a mouldy daycare centre
couldalsobeexplainedbysuchamechanism[19].Inarecent
study on young children, an inverse relationship was found
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Figure 2:Proposedmodelfor1,3-β-glucanactivityafterinhalation.
between home levels of 1,3-β-glucan and wheezing [20]. As
wheezing in this age group is caused by inﬂammation due to
viralinfections,theseresultssuggestabluntingoftheinﬂam-
matory response by 1,3-β-glucan.
Several studies report an increased incidence of infection
among school children in environments with mould with re-
mediation after cleaning [21–23]. This supports a concept of
a reduced resistance to pulmonary infections.
THE MODEL
Based upon the material reviewed above, a model for the ef-
fects of 1,3-β-glucan after inhalation is depicted in Figure 2.
The body has a number of defence mechanisms against
external challenges such as infectious, inﬂammagenic, and
allergenic agents. It is suggested that a prolonged exposure
to 1,3-β-glucan interferes with these defence mechanisms,
leading to an increased risk for disease. If the eﬀect of 1,3-β-
glucan is a threshold phenomenon, there will not be a dose-
response relationship with the exposure to moulds. Instead,
the dose-response for the eﬀective agent (e.g., endotoxin or
allergen) in theenvironment will be shifted downwards and
reﬂect sensitization. It is suggested that the model illustrated
in Figure 2 could be used for further explorations on the ef-
fects of exposure to 1,3-β-glucan and moulds in the environ-
ment.
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INTRODUCTION
Themajorcomponentsofthefungalcellwallarepolysaccha-
rides such as mannan, β-glucan, and chitin. β-glucan is the
major component, accounting for approximately 50% of the
cellwallmass[1,2].Itisbasicallyinsolubleinwaterandalka-
line solutions. In fungal infection diagnosis, serological and
molecular tests are used to detect the fungus antigen, anti-
body, or gene. These tests are important in the early diagno-
sis as a supplement to the clinical and mycological diagnosis.
The Limulus test using the 1,3-β-glucan-sensitive factor G is
useful for the screening of general fungal infections [3]. The
measuredvaluescorrelatewithclinicalsymptomsandpatho-
logical changes [4, 5].
Many researchers have examined the fungi-host rela-
tionship and antifungal protective immune mechanism. The
importance of innate immunity (i.e., macrophages, neu-
trophils) and cellular immunity (T-helper type 1 cells) in the
defense against fungi is widely acknowledged [6, 7]. Little is
known about the eﬀects of fungal antibody on the host re-
sponsetofungalinfection,andfewfungalantigenshavebeen
characterized for their ability to elicit the production of pro-
tective antibodies.
In this study, we examined the reactivity of the anti-β-
glucan antibody (anti-BGAb), the β-glucan-anti-BGAb in-
teraction in vivo and in vitro, and the role of this antibody
in fungal infections.
RESULTS AND DISCUSSION
The measurements of anti-BGAb titers of sera were
performed using an ELISA test, precoating with glu-
can preparations derived from various fungi. Binding of8 Mediators of Inﬂammation
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Figure 3: Comparison of reactivity of human immunoglobulin
(polyglobin N × 1000) to various antigen-coated plates. CSBG =
Candida solubilized cell wall β-glucan, ASBG = Aspergillus solubi-
l i z e dc e l lw a l lβ-glucan , GRN = Grifolan from G. frondosa, LPS =
lipopolysaccharide.
immunoglobulin was detected by peroxidase-conjugated an-
tibody against each immunoglobulin isotype. The titer and
reactivity of the anti-BGAb in healthy human volunteers
were examined. Five kinds of polyclonal human immune
globulin preparations were also tested.
Allseraandglobulinstestedcontainedanti-BGAb.There
was a tenfold or higher variation in anti-BG titer between
values from diﬀerent individuals but there was no signif-
icant diﬀerence between sampling occasions. Human nor-
mal immune globulin showed higher reactivity to Candida
solubilized BG (CSBG), a long β-1,6-linked glucan chain
attached to the β-1,3-glucan chain from Candida albicans
[8] and Aspergillus solubilized BG (ASBG), mainly com-
posed of β-1,3-glucan from Aspergillus niger [9]. There was
only a weak immune globulin response to GRN 6-branched
β-1,3-glucan from the mushroom Grifola frondosa [10]
(Figure 3).
The lower levels in subjects with infection may be caused
by attachment of the antibodies to cell wall β-glucan, sim-
ilar to the ﬁndings in mice where administration of whole
Candida c e l l sc a u s e dag r a d u a ld e c r e a s ei na n t i b o d yt i t e r s
[11]. The decrease in anti-BGAb titer could thus be related
to the progression of a fungal infection in patients with
mycosis.
Deep mycosis is a clinical problem also in animals. We
compared the titer and reactivity of anti-BGAb among sev-
eral animal species (monkey, horse, bovine, goat, pig, rab-
bit, mouse, dog, turkey, chicken) by ELISA, using plates pre-
coated with various standard β-glucans or polysaccharides.
Although species diﬀerences were present, anti-BGAb was
found in every species and showed high reactivity to glu-
can derived from pathogenic fungal cell wall. Furthermore,
we compared the anti-BGAb titer among fetal calf, calf and
bovine. Fetal calf sera had very low titers but they were
higher in calf and bovine sera. Also the titer was higher
in the bovine sera than calf sera. These results suggest that
anti-BGAb in native bovine sera is induced by fungi in the
environment.
To assess if anti-BGAb could act on Candida cells, we
measured its eﬀect on the candidacidal activity of human
macrophages derived from THP-1. Candida albicans cells,
anti-BGAb or control were added to the THP-1 and incu-
bated for 3 hours. After incubation, nonphagocytosed Can-
dida cells were collected and placed on YPG agar. anti-BGAb
enhancedthecandidacidalactivitywhichsuggeststhatitmay
modify the host defense against Candida through opsoniza-
tion.
We also examined the anti-BGAb interaction in vivo af-
ter administration of glucan. The anti-BGAb titer of DBA/2
mice which had received an intravenous dose of CSBG or
ASBG decreased in a dose-dependent manner as compared
to the titer before administration. These results suggest that
anti-BGAbinteractedwithpathogenicfungalcellwallglucan
speciﬁcally in vivo and that it was eliminated from the blood
as an antigen-antibody complex.
In a case study, anti-BGAb titers were measured in pa-
tients with aspergillosis (n = 2) and carinii pneumonia
(n = 3) and with 1,3-β-glucan positive sera.The averagetiter
in normals was 2371units/mL, compared to 414units/mL
among those with fungal infection. The patients had signif-
icantly lower titers compared with normal volunteers. The
anti-BGAb titer was reversely related to the clinical symp-
toms and galactomannan.
It has previously been reported that plasma levels of
1,3-β-glucan are elevated in dialysis patients [12]. We com-
pared the anti-BGAb titer of dialysis patients and healthy
volunteers. In dialysis patients, the titer was lower than
in healthy volunteers. Long-term (15–40 years) dialysis pa-
tients had lower titers than short-term (<5 years) dialysis
patients.
In conclusion, available data suggest that anti-BGAb
could play a role for β-glucan recognition and induce clear-
ance of pathogenic fungi and biological activity through
collaboration with other recognition molecules such as β-
glucan receptor or complement in human. Anti-BGAb inter-
acted with pathogenic fungal cell wall glucan in vivo and was
eliminated from the blood as an antigen-antibody complex.
Measurements of anti-BGAb could be useful as a response
index of pathogenic fungal cell wall β-glucan.
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THE SERUM β-GLUCAN ASSAY FOR THE DIAGNOSIS OF
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PURPOSE
To reexamine the eﬃcacy of serum β-glucan assay in the di-
agnosis of invasive fungal infection.
METHODS
A total of 456 autopsy records consecutive over the 6-year
period from January, 2000 to December, 2005 were reviewed
for the presence or absence of invasive fungal infection. The
sensitivity of the assay was calculated based on those cases
that were pathologically proved to be invasive fungal infec-
tions and had been tested for serum β-glucan within 2 weeks
beforedeath.Likewisethesensitivityofbloodculturewasob-
tained for comparison. The speciﬁcity of the β-glucan assay
was determined on those cases that had no evidence of inva-
sivefungalinfectionandhadhadaglucantestwithin2weeks
before death. The cutoﬀ was set at 30pg/mL, because the up-
perlimitofthenormalrangewas25pg/mL.Thepositiveand
negative predictive values of the test were estimated against
cutoﬀs at 30, 60, and 80pg/mL based on a model population
whose prevalence of invasive fungal infection was simulated
to that of the present series. In addition, the concordance be-
tween serum β-glucan assay and blood culture was studied
by reviewing all the records of blood culture over the same 6-
year period and collecting cases that grew fungi. Those who
had been tested for serum β-glucan within 2 weeks of blood
sampling for culture were selected and the concordance was
calculated.
RESULTS
Out of 456 autopsies, 54 (12%) had invasive fungal infec-
tions. Leukemias were the most frequent underlying disease
(52%), followed by lymphomas (13%) and AIDS (13%). The
most frequent causative fungus was Aspergillus (70%). Out
of the 54 cases with fungal infection, serum β-glucan was
m e a s u r e dw i t h i n2w e e k sb e f o r ed e a t hi n4 1c a s e s ,a n d3 9o f
those had a concentration higher than the cutoﬀ value. One
of the two negative cases was infected with Zygomycetes, a
fungus that does not produce β-glucan. With this case ex-
cluded,thesensitivityoftheserumβ-glucanassaywas97.5%
(39/40). Blood culture was performed in 48 of the 54 cases,
and four of them were positive for fungi. The sensitivity of
b l o o dc u l t u r ew a st h u so n l y8 . 3 % .
Out of 402 cases without fungal infections, 63 was tested
for serum β-glucan within 2 weeks before death, and 54 of
them showed the concentration lower than the cutoﬀ.T h u s ,
the speciﬁcity of β-glucan assay was 85.7%. The positive and
negative predictive values of the β-glucan assay were 46.3%
and 99.6% with cutoﬀ at 30pg/mL; 70.9% and 98.3% at
60pg/mL, and 87.0% and 97.4% at 80pg/mL.
During the same 6 years, there were 21 fungus-positive
blood cultures that were preceded or followed by serum β-
glucanmeasurementwithintwoweeks.Theconcentrationof
β-glucan was above 30pg/mL in 17 cases. The concordance
with blood culture, therefore, was 81% with the latter as a
gold standard.
CONCLUSION
Serum β-glucan assay is a highly sensitive and highly spe-
ciﬁc test for invasive fungal infection. With a cutoﬀ set at
80pg/mL, the test will rule in or rule out the diagnosis of in-
vasive fungal infection with about 90% probability in hospi-
tals where many patients with haematological malignancies
and cancers are cared for.10 Mediators of Inﬂammation
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INTRODUCTION
Peptide antibiotics exhibit potent antimicrobial activities
against both Gram-positive and Gram-negative bacteria,
fungi, and viruses, and they form one group of eﬀec-
tor components in the innate host defense system. The
peptide-based defense in mammals against invading mi-
crobes relies on the two evolutionally distinct groups
of antimicrobial peptides, defensins, and cathelicidins,
which have been identiﬁed in several epithelial tissues
and in the granules of phagocytes. About 30 cathelicidin
members have been identiﬁed from various mammalian
species; however, only one cathelicidin hCAP18 (hu-
man cationic antibacterial protein of 18kDa) has been
found in humans, and its carboxyl terminal antibacterial
peptide called LL-37 comprising 37 amino acid residues
(L1LGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES37)
hasbeenidentiﬁed.Secondary-structurepredictionsindicate
that LL-37 adopts an α-helical amphipathic conformation;
the helical wheel regions are clearly amphipathic and
subtended by the hydrophilic (positively charged) and
hydrophobic sectors.
Among antibacterial peptides, defensins completely lose
their antibacterial activities in the extracellular milieu con-
taining a physiological concentration of NaCl (150mM)
and serum. In contrast, LL-37 can exhibit antibacterial ac-
tivities against Gram-negative and Gram-positive bacteria
under these conditions. Furthermore, LL-37 can bind to
lipopolysaccharide (LPS) and neutralize its biological activi-
ties. Thus, LL-37 and its related derivatives could be attrac-
tive candidates for therapeutic agents that can be used not
only for bacterial infections but also endotoxin shock/sepsis
caused by Gram-negative bacterial infections.
A short fragment peptide (18-mer; K15 to V32)o fL L - 3 7
displayed an amphipathic α-helical structure as illustrated in
Figure 4.
This fragment possessed antibacterial and LPS-
neutralizing activities almost equal to those of the parent
LL-37 peptide. To develop the cathelicidin-derived antimi-
crobial peptides with enhanced biological activities, we
utilized the 18 mer peptide (K15-V32) of human cathelicidin
LL-37 (L1-S37) as a template, and evaluated the activities
of its peptide derivatives [1, 2]. By replacement of E16 and
K25 with two L residues, hydrophobicity of the peptide
was increased, and hydrophobic sector in the helix was
extended (Figures 1 and 2; 18-mer K15-V32 versus 18-mer
LL). Concomitantly, pI value was increased from 11.50 to
12.22. Furthermore, by replacement of Q22,D 26,a n dN 30
with three K residues, hydrophilicity of the peptide was
enhanced, and positively charged hydrophilic sector in the
helix was expanded (18-mer LL versus 18-mer LLKKK),
accompanied with the further increase of pI value from
12.22 to 12.82.
ANTIBACTERIAL ACTIVITIES 18-MER PEPTIDES
Antibacterial activities of the peptides were assessed by ala-
marBlue assay using Staphylococcus aureus (MSSA, meth-
icillin-sensitive Staphylococcus aureus; MRSA methicillin-
resistant Staphylococcus aureus), Escherichia coli, Streptococ-
cus pneumoniae, Streptococcus pyogenes,a n dPseudomonas
aeruginosa as target organisms [1]. The 18-mer peptides as
well as LL-37 inhibited the growth of these bacteria, and 18-
mer LLKKK was the most potent among the peptide deriva-
tives (Figure 5).
To further elucidate the mechanism for the antibac-
terial actions of LL-37-derived peptides, we assessed their
membrane-permeabilization activities using E. coli ML-35p
as a target organism. The peptide derivatives induced the
outer and inner membrane permeabilization. The 18-mer
LLKKK was the most potent among the LL-37-derived pep-
tides at inducing the outer- and inner-membrane permeabi-
lizations [1].
LPS-NEUTRALIZING ACTIVITIES OF
18-MER PEPTIDES
Further, we evaluated the LPS-neutralizing activities of LL-
37-derived peptides by examining their eﬀects on the bind-
ing of FITC-conjugated LPS to CD14-positive cells using
a murine macrophage cell line RAW 264.7 [2]. The18-mer
peptides as well as LL-37 suppressed the binding of FITC-
conjugated LPS to RAW 264.7 cells, and 18-mer LLKKK
was the most potent among the peptides tested at inhibit-
ing the binding of FITC-conjugated LPS to RAW 264.7 cells
(Figure 5). We also revealed that the 18-mer K15-V32, 18-mer
LL, and 18-mer LLKKK peptides have a potential to bind to
LPS, and 18-mer LLKKK was the most potent at binding to
LPS and inhibiting LPS-LBP interaction [2].
Using D-galactosamine-sensitized mice, we assessed the
eﬀects of 18-mer peptides on lethal LPS activity in vivo [2].
The administration of 18-mer K15-V32, 18-mer LL, 18-mer
LLKKK, or LL-37 increased the survival rate, and 18-mer
LLKKK administration was the most protective. In agree-
ment with this, administration of an 18-mer peptide or LL-
37 markedly lowered the LPS-induced increase in serum
TNF-α levels, and 18-mer LLKKK had the largest eﬀect.
PERSPECTIVE
For prevention of bacterial infections, much attention has
focused on the low-molecular-weight cationic antimicro-
bial peptides. Bacterial membrane contains large amounts
of negatively charged phospholipids such as phosphatidyl-
glycerol and cardiolipin. Thus, the cationic amphipathic an-
timicrobial peptides show high aﬃnities for bacterial mem-
branecomponentsandkillbacteriabypermeabilizingand/or
disrupting bacterial membranes. Moreover, the positivelyEuropean Brain and Behaviour Society 11
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Figure 4:HelicalwheelprojectionsforLL-37andits18-merpeptidederivatives.Positivelychargedresiduesareinwhitecircles,hydrophobic
residues are in black circles, neutral hydrophilic residues are in gray circles, and negatively charged residues are boxed.
chargedamphipathicstructuresofantimicrobialpeptidesare
assumed to be important for interaction with a negatively
charged amphipathic LPS.
We have revealed that by modifying the hydrophobicity
and cationicity of the amphipathic α-helical antimicrobial
peptide (LL-37-derived 18-mer peptide), the in vitro and in
vivo biological (antibacterial and LPS-neutralizing) activities
ofthepeptidecouldbeenhanced[1,2].Ontheotherhand,it
has been demonstrated that high concentrations of cationic
antimicrobial peptides are occasionally toxic to host cells [3]
and that cytotoxicity is correlated with the extent of the hy-
drophobic regions in the peptides [4]. Although many prob-
lems still need to be solved, antimicrobial peptides could be-
comeoneofthenewclassesofantibioticsthatcanbeusedfor
treatment of bacterial infections and their related symptoms
in the future.
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CONCLUDING REMARKS
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The knowledge on 1,3-β-glucan has increased tremendously
since the ﬁrst glucan workshop in 1990 [1]a n dat e x t b o o k
is now available on the toxicity of diﬀerent forms of 1,3-β-
glucan after diﬀerent modes of administration [2]. The un-
derstanding of the eﬀects of 1,3-β-glucan is complicated by
the many steric forms present and also by the simultane-
ous presence of other agents in environments where 1,3-β-
glucans are present. Regarding the neutrophil-based acute
inﬂammatory response it seems as if nonwater soluble 1,3-
β-glucan cannot elicit this response whereas water soluble
forms and high doses may do so. A major advance in the
knowledge has been the identiﬁcation of a speciﬁc receptor
and the development of speciﬁc antibodies which will facil-
itate the estimates of exposure both in clinical cases and in
the general population. Determinations of 1,3-β-glucan in
serum have become established as a clinical tool in deep my-
cosisandworkisunderwaytofurtherevaluatetheroleof1,3-
β-glucan in pulmonary diseases. A major enigma is still the
eﬀect of 1,3-β-glucan on the immune system after chronic
exposureandhowthiscouldrelatetotheriskforallergicsen-
sitizationandthesuppressiveeﬀectsontumorgrowthseenin
some early animal models. Hopefully the proceedings from
this glucan workshop will not only point to the importance
of 1,3-β-glucan in the clinical and general environment but
also stimulate further research.
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